Wugen, Inc.
Clinical trials sponsored by Wugen, Inc., explained in plain language.
-
New immune cell therapy shows promise for tough leukemia
Disease control CompletedThis early-phase study tested a new treatment called WU-NK-101 in 9 adults with acute myeloid leukemia (AML) that had returned or not responded to standard therapy. The treatment uses specially grown natural killer cells from a donor to attack the cancer. The main goals were to c…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated May 01, 2026 16:26 UTC
-
Immune cells from donors target deadly blood cancers in early trial
Disease control CompletedThis early-phase study tested a new treatment called WU-CART-007 in 28 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that had come back or not responded to standard therapy. The treatment uses donor immune cells engineered to find and attack cancer cel…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC